Physiomics has just dropped one of those RNS announcements that makes you sit up and actually read past the headline numbers. And while the 46% revenue surge and shrinking losses are impressive enough, the real story here is in the strategic shifts powering this growth.
Not Just Beating Expectations, But Beating Them Convincingly
For the year ending June 2025 (FY25), Physiomics expects unaudited results showing:
- Total Income: £834k (a 46% jump on FY24)
- Loss After Tax: £419k (a 31% reduction on FY24)
This isn’t just scraping past forecasts; it’s comfortably exceeding them. It signals a company hitting its operational stride.
The Engine Room: Contract Wins & Pipeline Strength
Digging deeper, the foundations for this performance – and future growth – look robust:
- Record Contract Value: The average value of contracts secured over FY24 and FY25 hit over £1 million per year. That’s a whopping 63% higher than the yearly average of the preceding five years.
- Strong FY26 Starting Point: The company enters the new financial year (FY26) with approximately £593k in contracted revenue already in the bag for recognition this year. That’s an 18.6% increase on the £500k carried forward into FY24. Add to this an expected £60k in Grant Income, and the baseline for FY26 looks significantly stronger.
This isn’t accidental growth; it’s the result of a concerted business development push that’s clearly bearing fruit.
Strategic Shifts Driving Momentum
Beyond the raw financials, Physiomics is demonstrably executing on key strategic initiatives designed to reduce risk and fuel sustainable expansion:
1. Service Line Expansion: Biometrics Takes Off
June 2025 saw the announcement of Physiomics’ first two dedicated Biometrics contracts, worth £111k. Critically, they’ve also recruited Jesse Thissen as Head of Biometrics, signalling serious intent to build this capability.
2. Client Base Diversification: Reducing Reliance
A standout stat: 31% of all FY25 contract awards came from new clients. Contrast that with an average of just 17% over the prior six years. This is crucial for reducing client concentration risk.
3. Therapeutic Area Expansion: Beyond Oncology
Historically anchored in oncology, Physiomics is breaking out. A remarkable 50% of projects delivered in FY25 were in therapeutic areas outside oncology. This compares to an average of just 5% over the previous three years. This diversification massively expands their addressable market.
4. Personalised Medicine: Building the Future
The expanded relationship with DoseMe Inc, including implementing Physiomics’ dosing software onto the DoseMeRx platform, is a tangible step towards scalable solutions. Progress with the PREDICT-ONC trial further underpins their commitment to this high-growth area.
Leadership Confidence: “Changes We’ve Made”
CEO Dr. Peter Sargent’s comment cuts to the chase: “I am thrilled that the changes we’ve made here at Physiomics are starting to have a positive effect…”. This isn’t just market fluff. The numbers – the revenue jump, the shrinking loss, the record contracts, the diversification stats – all point to effective operational and strategic changes taking root.
His confidence about FY26, backed by that record opening contracted revenue position, suggests this isn’t viewed as a one-off spike, but the beginning of a sustained trajectory.
The Takeaway: More Than Just a Good Year
Physiomics’ FY25 results are undoubtedly positive, exceeding expectations on core metrics. However, the more compelling narrative lies in the strategic transformation underway:
- Diversification: Both in clients and therapeutic areas, reducing reliance on any single sector.
- Service Expansion: Building out Biometrics as a key revenue stream alongside core modelling.
- Scalable Tech: Progress in personalised medicine through partnerships like DoseMeRx.
- Commercial Momentum: Record contract values and a stronger opening position for FY26.
This RNS paints a picture of a company moving beyond its niche, actively de-risking its business model, and building the foundations for more predictable, diversified growth. The challenge now is maintaining this momentum and translating the reduced losses into that coveted path to profitability. Based on this update and the strategic pillars they’re building, they’ve certainly given themselves a fighting chance.
Physiomics plc (AIM: PYC) | Broker: Hybridan LLP | NOMAD: Strand Hanson Ltd | www.physiomics.co.uk
